{
  "success": true,
  "applicability": {
    "isApplicable": false,
    "reasons": [
      {
        "type": "condition",
        "description": "Patient does not have required condition: atherosclerotic cardiovascular disease",
        "details": "The study required patients to have atherosclerotic cardiovascular disease"
      },
      {
        "type": "medication",
        "description": "Patient is not on required medication: statin therapy",
        "details": "The study required patients to be taking statin therapy"
      },
      {
        "type": "biomarker",
        "description": "Missing biomarker data: LDL cholesterol",
        "details": "The study results are based on LDL cholesterol levels, which are not in the patient's records"
      }
    ]
  },
  "patientSummary": {
    "age": 52,
    "sex": "male",
    "relevantBiomarkers": [],
    "relevantConditions": [
      "Type 2 Diabetes Mellitus",
      "Essential Hypertension",
      "Hyperlipidemia"
    ],
    "relevantMedications": [
      "Metformin 1000mg",
      "Lisinopril 10mg",
      "Atorvastatin 20mg"
    ]
  },
  "paperSummary": {
    "intervention": "evolocumab (either 140 mg every 2 weeks or 420 mg monthly)",
    "primaryEndpoint": "composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization",
    "population": "Patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy.",
    "followUp": "2.2 years median"
  }
}